Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target <i>Clostridioides difficile</i>
The US Centers for Disease Control and Prevention (CDC) lists <i>Clostridioides difficile</i> as an urgent bacterial threat. Yet, only two drugs, vancomycin and fidaxomicin, are approved by the FDA for the treatment of <i>C. difficile</i> infections as of this writing, while...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/15/5/623 |